NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 208)
Posted On: 06/03/2022 7:56:44 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s six clinical domains (existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum) and reviews the strengths and limitations of existing psychedelic-assisted psychotherapy approaches and evidence-based therapies. In addition, the company also announced it has created a 28-member team of faculty and advisors who will lead the company’s EMBARK Psychedelic Facilitator Training Program. Recognized leaders in their field, the team members will oversee Cybin’s innovative new program. “It’s a pleasure to see our work published in this respected journal,” said Cybin chief clinical officer and EMBARK cocreator Alex Belser in the press release. “In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We’d like to honor the contributions of many teachers and leaders in the field who have helped chart this course.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s six clinical domains (existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum) and reviews the strengths and limitations of existing psychedelic-assisted psychotherapy approaches and evidence-based therapies. In addition, the company also announced it has created a 28-member team of faculty and advisors who will lead the company’s EMBARK Psychedelic Facilitator Training Program. Recognized leaders in their field, the team members will oversee Cybin’s innovative new program. “It’s a pleasure to see our work published in this respected journal,” said Cybin chief clinical officer and EMBARK cocreator Alex Belser in the press release. “In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We’d like to honor the contributions of many teachers and leaders in the field who have helped chart this course.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼